[1] 李东丹, 张晶, 王国丽,等. 儿童进行性家族性肝内胆汁淤积症4例临床分析. 中国实用儿科杂志, 2021.
[2] 刘小菊, 武丽娜, 刘立伟,等. 19例进行性家族性肝内胆汁淤积的临床及病理特点分析. 肝脏, 2022, 27(5):5.
[3] 翟丽娟, 杜鹃, 王能里,等. 18q21杂合缺失致婴儿肝内胆汁淤积症伴智能发育落后1例病例报告. 中国循证儿科杂志, 2018, 13(2):4.
[4] 何佳倩, 孙长宇, 乔芳芳,等. 进行性家族性肝内胆汁淤积症2例临床及遗传学分析. 临床儿科杂志, 2021, 39(7):4.
[5] 中华医学会肝病学分会. 胆汁淤积性肝病管理指南(2021). 中华肝脏病杂志, 2022, 30(03):253-263.
[6] 丘燕燕, 熊小丽, 汤建桥,等. ABCB11基因多位点突变致进行性家族性肝内胆汁淤积症2型1例病例报告. 中国循证儿科杂志, 2020, 15(6):2.
[7] 杨秀芳, 柳国胜, 陈玉兰,等. 胃肠外营养相关性胆汁淤积症早产儿血MDR3基因mRNA表达. 中国当代儿科杂志, 2019(2):6.
[8] 翁宇航, 熊清芳, 刘杜先,等. 进行性家族性肝内胆汁淤积症3型临床病理特征分析. 临床肝胆病杂志, 2022, 38(1):6.
[9] 甘川, 许红梅. 进行性家族性肝内胆汁淤积3型1例临床特点及基因突变分析. 中国实用儿科杂志, 2022(037-004).
[10] Lipiński P, Ciara E, Jurkiewicz D, et al. Progressive familial intrahepatic cholestasis type 3: report of four clinical cases, novel ABCB4 variants and long-term follow-up. Ann Hepatol, 2021, 25: 100342.
[11] Ruiz-Casas L, O'Hara S, Mighiu C, et al. Burden of illness of progressive familial intrahepatic cholestasis in the US, UK, France, and Germany: study rationale and protocol of the PICTURE study. Expert Rev Pharmacoecon Outcomes Res, 2021, 21(2): 247-253.
[12] 朱磊, 朱俊岭, 钮明杨, 等. 熊去氧胆酸对婴儿肝炎综合征炎症细胞因子的影响. 中国病理生理杂志, 2015, 31(6): 1142-1144.
[13] 谭婷, 王岩, 涂柳, 等. 4-苯基丁酸钠通过抑制内质网应激减轻皮层神经元氧糖剥夺/再灌注损伤. 中国生物化学与分子生物学报, 2018, 34(1): 53-60.
[14] Almes M, Jobert A, Lapalus M, et al. Glycerol phenylbutyrate therapy in progressive familial intrahepatic cholestasis type 2. J Pediatr Gastroenterol Nutr, 2020, 70(6): e139-e140.
[15] Baumann U, Sturm E, Lacaille F, et al. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study. Clin Res Hepatol Gastroenterol, 2021, 45(5): 101751.
[16] Li Q, Chong C, Sun R, et al. Long-term outcome following cholecystocolostomy in 41 patients with progressive familial intrahepatic cholestasis. Pediatr Surg Int, 2021, 37(6): 723-730.
[17] Slavetinsky C, Sturm E. Odevixibat and partial external biliary diversion showed equal improvement of cholestasis in a patient with progressive familial intrahepatic cholestasis. BMJ Case Rep, 2020, 13(6): e234185.
[18] Alrabadi L S, Morotti R A, Valentino P L, et al. Biliary drainage as treatment for allograft steatosis following liver transplantation for PFIC-1 disease: a single‐center experience. Pediatr Transplant, 2018, 22(4): e13184.
[19] Foroutan H R, Bahador A, Ghanim S M, et al. Effects of partial internal biliary diversion on long-term outcomes in patients with progressive familial intrahepatic cholestasis: experience in 44 patients.Pediatr Surg Int, 2020, 36(5): 603-610.
[20] Jannone G, Stephenne X, Scheers I, et al. Nasobiliary drainage prior to surgical biliary diversion in progressive familial intrahepatic cholestasis type Ⅱ.Eur J Pediatr, 2020, 179(10): 1547-1552.
[21] Gül-Klein S, ?llinger R, Schmelzle M, et al. Long-term outcome after liver transplantation for progressive familial intrahepatic cholestasis. Medicina, 2021, 57(8): 854.
[22] Henkel S A F, Salgado C M, Reyes‐Mugica M, et al. Long‐term liver transplant outcomes for progressive familial intrahepatic cholestasis type 1: the Pittsburgh experience. Pediatr Transplant, 2021, 25(8): e14108. |
